DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/c20e72/multiple_myeloma_t) has
announced the addition of the "Multiple Myeloma Therapeutics - Global Strategic
Business Report" report to their offering.
This report analyzes the U.S. market for Multiple Myeloma Therapeutics in
Millions of US$. The market for multiple myeloma therapeutics is analyzed by the
following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for
multiple myeloma therapeutics is also analyzed by the Lines of Treatment -
Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates,
and Therapy for Relapsed or Refractory Myeloma. Annual forecasts are provided
for the period of 2006 through 2015. The report profiles 98 companies including
many key and niche players such as Amgen Inc., Avalon Pharmaceuticals, Inc.,
Bristol-Myers Squibb Company, Kosan Biosciences, Inc., Celgene Corporation, F.
Hoffmann-La Roche Ltd, Genentech, Inc., Genta Incorporated, Millennium
Pharmaceuticals, Ortho Biotech Products, LP, Seattle Genetics, and Ziopharm
Oncology, Inc. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II. A U.S. MARKET REPORT
1. Industry Overview
2. Disease & Treatment Overview
3. Clinical Trials and Drug Approvals
4. Recent Industry Activity
5. Focus on Select Players
6. Market Perspective
III. COMPETITIVE LANDSCAPE
For more information visit
http://www.researchandmarkets.com/research/c20e72/multiple_myeloma_t
Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com
Copyright Business Wire 2009
